Market Report, "Global Alzheimers Drugs Market 2014-2018", published

Alzheimer’s disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and affects women more than men. Globally, 35 million people are suffering from AD and this number is expected to double by 2030. AD arises due to the failure of synaptic transmission, which results in eventual death of the neurons present in the brain. AD is characterized by the accumulation of beta-amyloid plaques outside and around the neurons and the formation of neurofibrillary tangles inside the nerve cells. Neuronal loss associated with AD leads to a reduction in brain size and deposition of debris from dead and dying neurons inside the brain. AD can be categorized into Early-onset AD, Late-onset AD, and Familial AD. Early-onset AD is a rare form of AD that affects people younger than 65 years of age. Late-onset AD is the most prevalent form of AD and usually affects people aged 65 years or above. Familial AD is the inheritable form of AD with least prevalence among the three.

TechNavio’s analysts forecast the Global Alzheimer’s Disease Drugs market will grow at a CAGR of 2.61 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Alzheimer’s Disease Drugs market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat dementia associated with Alzheimer’s disease.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Alzheimer’s Disease Drugs market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, the Global Alzheimer’s Disease Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Alzheimer’s Disease Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

Key Vendors

Other Prominent Vendors

Key Market Driver

Key Market Challenge

Key Market Trend

Key Questions Answered in this Report

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

Companies Mentioned in this Report: Eisai Co. Ltd, Forest Laboratories Inc., Janssen Pharmaceuticals Inc., Novartis AG, Adamas Pharmaceuticals Inc., Archer Pharmaceuticals Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., H. Lundbeck A/S, Merck & Co. Inc., MorphoSys AG, Otsuka Pharmaceutical Development & Commercialization Inc./ Otsuka America Pharmaceutical Inc., Takeda Pharmaceutical Co. Ltd, TauRx Pharmaceuticals Ltd., Zinfandel Pharmaceuticals Inc.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world’s top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.